BusinessUK

Wellcome Trust launches Venture Capital arm

21.03.2012 - The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma, will draw its initial capital from the trust’s endowment.

„Although Sigma has the primary goal of generating excellent returns for the Wellcome Trust, its investments will also provide emerging businesses in the healthcare sector with a valuable new source of funding and guidance“, the Wellcome Trust stated. In recent years, the charity, which hands out £600 million in research grants every year and has a £14 billion endowment, has substantially increased its private equity holdings. On 30 September 2011 it has invested £2.7bn in venture capital firms. The trust has recruited Martin Murphy, previously a partner at venture capital firm MVM Life Science Partners, as Sigma’s chief executive and Oxford Instruments and Deltex Medical chairman Nigel Keen to chair Sigma’s board. As everywhere, British biotech start-ups are struggling to find new funding, and venture capital players have been called conservative in their investments in drug developers in recent years. Therefore, new funding mechanisms are met with cheers. Glyn Edwards, interim chief executive at the BioIndustry Association trade body, expects a significant boost to companies developing new medicines: „It is especially pleasing to see that the fund will take a long term view and provide companies with the support they need to reach their full potential.” 

http://www.european-biotechnology-news.com/news/news/2012-01/wellcome-trust-launches-venture-capital-arm.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products